Halozyme Therapeutics's quarterly market cap
declined
from Sep. 2023 ($5,045.5 Mil) to Dec. 2023 ($4,685.4 Mil) but then
increased
from Dec. 2023 ($4,685.4 Mil) to Mar. 2024 ($5,173.9 Mil).
Halozyme Therapeutics's annual market cap
increased
from Dec. 2021 ($5,528.8 Mil) to Dec. 2022 ($7,690.3 Mil) but then
declined
from Dec. 2022 ($7,690.3 Mil) to Dec. 2023 ($4,685.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Halozyme Therapeutics's Enterprise Value for Today is $6,529.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Halozyme Therapeutics's Market Cap
For the Biotechnology subindustry, Halozyme Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Market Cap falls into.
Halozyme Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Halozyme Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (NAS:HALO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Halozyme Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 